Skip to main content
. 2017 Jun 28;77(12):1263–1280. doi: 10.1007/s40265-017-0769-2

Table 2.

Capsid inhibitors and core protein allosteric modifiers currently undergoing trials

Drug/compound Clinical study
Morphothiadin (GLS4) Phase II
AL-3778 (formerly NVR 3-778) Phase II
RO6864018 Phase II
AIC 649 Phase I
JNJ56136379 Phase I
HBV CpAM Preclinical
AB-423 Preclinical

CpAM core protein allosteric modifier, HBV hepatitis B virus